Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713030 | 0.91 | CNR1 (0.56) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL1713229 | 0.89 | POLB (0.55) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL1722857 | 0.89 | CNR1 (0.56) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL1712628 | 0.87 | FAAH (0.51) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL1713125 | 0.86 | POLB (0.53) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL1712996 | 0.86 | POLB (0.50) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL5286229 | 0.82 | POLB (0.55) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL13744070 | 0.81 | POLB (0.48) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL13744221 | 0.80 | POLB (0.47) | POLBSMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL1712872 | 0.79 | AKR1C3 (0.55) | POLBSMN1; SMN2KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691846-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691846-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202888-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202888-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2252587-B1 | PIPERIDINE SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | POLB 3190/4885SMN1; SMN2 514/4885KMT2A 201/4885 |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | POLB 3190/4885SMN1; SMN2 514/4885KMT2A 201/4885 |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | POLB 3190/4885SMN1; SMN2 514/4885KMT2A 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.